Skip to content
Peptide research

GHRP-2

Also known as Pralmorelin
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic growth hormone secretagogue (ghrelin-receptor agonist), marketed for anti-aging, body composition, and sleep. Its one solid effect is raising growth hormone, which supports its use as a GH-deficiency diagnostic. The fat-loss and sleep benefits people want stay speculative in humans. Being non-selective, it also raises appetite, cortisol, and prolactin, plus water retention and joint pain. Not an approved US drug, and banned in competitive sport.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

GHRP-2 (Growth Hormone Releasing Peptide-2), also known as pralmorelin, is a synthetic 6-amino-acid peptide that stimulates your body's natural release of growth hormone. It was the first peptide of its kind to be used clinically, mimicking the hunger hormone ghrelin to trigger growth hormone release from the pituitary gland. GHRP-2 is marketed in Japan as GHRP Kaken 100 for diagnosing growth hormone deficiency but has never been approved for therapeutic use elsewhere.

How it works in the body

Binds to the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus, directly stimulating growth hormone release. It also suppresses somatostatin (the hormone that inhibits GH release), creating a dual-action boost. Has the strongest GH-releasing effect of the GHRP family but also stimulates appetite via ghrelin pathways.

Research overview

GHRP-2 is one of the most extensively studied growth hormone-releasing peptides, with human clinical data spanning from the mid-1990s through the 2020s. It works by activating the ghrelin receptor in the brain and pituitary gland, triggering a robust growth hormone release — up to 13 times greater than placebo in clinical studies. Beyond growth hormone, it also significantly increases appetite (about 36% more caloric intake in studies) and raises cortisol and prolactin levels, which distinguishes it from cleaner alternatives like ipamorelin. Safety studies in children established its half-life at roughly 33 minutes. It reached Phase II trials for growth hormone deficiency treatment but was never approved, partly because its effectiveness drops substantially in patients who actually have GH deficiency compared to healthy individuals.

Who researches GHRP-2?

Commonly researched by

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

  • People researching potent growth hormone release

    One of the primary studied benefits of GHRP-2.

Important considerations for

  • Those with Active cancer

    High

    Potent GH secretagogue — GH/IGF-1 elevation promotes tumor growth.

  • Those with Diabetes/insulin resistance

    Moderate

    GH elevation can worsen blood sugar control.

  • Those with Obesity with appetite issues

    Moderate

    GHRP-2 strongly stimulates appetite via ghrelin pathway.

  • Those with Diabetic retinopathy

    High

    GH/IGF-1 axis activation can accelerate retinal damage.

Safety & interactions

Do not use if

  • Active cancer

    High

    Potent GH secretagogue — GH/IGF-1 elevation promotes tumor growth.

  • Diabetic retinopathy

    High

    GH/IGF-1 axis activation can accelerate retinal damage.

  • Diabetes/insulin resistance

    Moderate

    GH elevation can worsen blood sugar control.

  • Obesity with appetite issues

    Moderate

    GHRP-2 strongly stimulates appetite via ghrelin pathway.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Reliably increases hunger and food intake (~36%)

    High

    PMID 15699539 (Laferrere 2005)

  • Stimulates the HPA axis, raising ACTH and cortisol

    Moderate

    PMID 9285939 (Arvat 1997); PMID 20431231 (Kimura 2010, direct ACTH-releasing activity)

  • Stimulates prolactin release

    Low

    PMID 9285939 (Arvat 1997)

  • GH/IGF-1 elevation causes water retention (bloating, joint pain)

    Moderate

    GH/IGF-1 class-effect literature; MK-677 secretagogue data (no GHRP-2-specific quantification located)

  • Carpal-tunnel-type symptoms from fluid retention/IGF-1

    Low

    GH/IGF-1 and MK-677 class-effect literature (no GHRP-2-specific report located)

  • Flushing from ghrelin receptor activation

    Low

    PMDA GHRP KAKEN100 Injection prescribing information, section 11.2: facial flushing is listed with frequency unknown.

Interaction summary(5)

Rated by direction with this peptide

  • GHRH and GHRH analogs (CJC-1295, sermorelin, tesamorelin)

    SynergisticModerate

    Acts on a distinct receptor and suppresses somatostatin, producing supra-additive GH/IGF-1 release with GHRH (combination gave a further ~2-fold GH rise and +40% IGF-1 in the Van den Berghe RCT) — the basis of combined provocative testing, but it also amplifies total GH/IGF-1 exposure.

    PMID 9024260 (Van den Berghe 1997); PMID 9285939 (Arvat 1997)

  • Somatostatin analogs (octreotide, lanreotide)

    CautionModerate

    Somatostatin opposes GH secretion and blunts secretagogue-stimulated GH release, so concurrent analog therapy markedly reduces GHRP-2 efficacy (and can confound GHRP-2-based diagnostic testing). Mechanism-based; no direct co-administration trial cited.

    GH neuroendocrine physiology (somatostatin suppression of GHS-stimulated GH)

  • Insulin and antidiabetic medications

    CautionTheoretical

    GH is counter-regulatory (anti-insulin); sustained GH/IGF-1 elevation can impair glucose tolerance and blunt glycemic control, though short pulsatile GHRP-2 dosing makes the effect modest and largely theoretical.

    GH/IGF-1 class effect on insulin sensitivity; MK-677 metabolic data

  • Glucocorticoids (chronic/high-dose corticosteroids)

    CautionLow

    Chronic glucocorticoid excess blunts the somatotroph GH response to secretagogues; additionally GHRP-2's own transient ACTH/cortisol rise (Arvat 1997) can confound adrenal-axis interpretation and testing.

    PMID 9285939 (Arvat 1997, ACTH/cortisol effect); endocrine physiology of steroid GH suppression

  • Other ghrelin-receptor agonists (MK-677, GHRP-6, hexarelin, ipamorelin, ghrelin)

    CautionLow

    Share the same GHS-R1a receptor, so combining offers little additive GH benefit (shared receptor, potential desensitization) while compounding ghrelin-mediated effects such as appetite, cortisol and prolactin.

    PMID 9285939 (shared GHS-R1a pharmacology across GHRPs)

Known risks(8)

  • Cortisol and ACTH elevation

    Moderate

    GHRP-2 stimulates the HPA axis, raising ACTH and cortisol levels comparable to CRH stimulation. Chronic elevation may cause stress-related symptoms, immune suppression, and metabolic disruption.

  • Prolactin elevation

    Moderate

    Stimulates prolactin release, though less than TRH. Chronically elevated prolactin may cause diminished libido, gynecomastia in males, and menstrual irregularities in females.

  • Marked appetite increase and weight gain

    Moderate

    As a ghrelin mimetic, GHRP-2 reliably increases hunger and food intake by ~36%. This can lead to unintended weight gain, particularly problematic for those using it for body composition.

  • Fluid retention

    Mild to moderate

    Elevated GH and IGF-1 levels cause water retention, which may manifest as bloating, joint stiffness, or peripheral edema.

  • Tingling and numbness (paresthesias)

    Mild

    Attributed to nerve compression from fluid retention or direct effects of elevated IGF-1. Commonly reported in hands and feet.

  • Flushing

    Mild

    Reported in clinical studies, likely related to vasodilatory effects of ghrelin receptor activation.

  • Unregulated product quality

    High

    Since GHRP-2 is not available through legitimate pharmacies in most countries, users rely on unregulated products sold online with no pharmaceutical quality assurance, risking contamination, incorrect dosing, or degraded product.

  • Potential for IGF-1-related cancer risk

    Theoretical — unstudied long-term

    Chronic GH/IGF-1 elevation is epidemiologically associated with increased risk of certain cancers. Long-term safety of sustained GHRP-2 use is unstudied.

Drug interactions(7)

  • GHRH (e.g., sermorelin, tesamorelin)

    Monitor — intentional synergy

    Synergistic — co-administration produces markedly greater GH release than either agent alone, as they act through different receptor pathways (GHS-R1a vs GHRH-R). Used intentionally in some diagnostic and therapeutic protocols.

  • Somatostatin and analogs (octreotide, lanreotide)

    Significant

    Antagonistic — somatostatin inhibits GH release and may blunt or abolish GHRP-2's GH-stimulating effects.

  • Exogenous growth hormone (somatropin)

    Moderate

    Additive GH/IGF-1 elevation increases risk of side effects (fluid retention, insulin resistance, joint pain). Negative feedback from exogenous GH may also reduce endogenous GH response to GHRP-2.

  • Insulin and oral hypoglycemics

    Moderate

    GH is a counter-regulatory hormone that opposes insulin action. GHRP-2-induced GH elevation may worsen insulin resistance and impair glycemic control in diabetic patients.

  • Glucocorticoids (prednisone, dexamethasone)

    Moderate

    Chronic glucocorticoid use blunts GH response to secretagogues. GHRP-2 itself elevates cortisol, so combined use may compound HPA axis effects.

  • Dopamine agonists (cabergoline, bromocriptine)

    Low — potentially beneficial

    May counteract GHRP-2-induced prolactin elevation. Sometimes used concomitantly to manage prolactin side effects.

  • Other GH secretagogues (ipamorelin, GHRP-6, MK-677)

    Moderate

    Overlapping mechanism at GHS-R1a. Combining multiple secretagogues increases risk of excessive GH/IGF-1 elevation and receptor desensitization.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
50
Human Studies
15

Human clinical data from ~15 published studies including Phase I PK/PD in children (n=10), diagnostic studies in short-stature children (n=24), comparative endocrine studies in young and elderly adults (n=12), food intake studies in healthy men (n=7), critical illness RCT (n=33), and diagnostic evaluation in hypothalamic-pituitary disorders (n=36). Approved as diagnostic agent in Japan. Never progressed past Phase II for therapeutic indications due to reduced efficacy in GHD patients and complex side effect profile.

Researched for(7)

Rated by confidence in the evidence

  • Potent growth hormone release

    High

    Human trials show a large GH rise, roughly 13-fold over placebo in one study.

    PMID 15699539 (Laferrere 2005); PMID 9285939 (Arvat 1997); PMID 9024260 (Van den Berghe 1997, GHRP-2 4-6x GH rise)

  • Diagnostic tool for GH deficiency

    Medium

    Approved in Japan and validated in human trials as a GH deficiency test.

    PMID 17609397 (Chihara 2007, simple GHRP-2 test in adult GHD, 15 ug/L cutoff); PMC9249372 (clinical usefulness of GHRP-2 test)

  • Appetite stimulation and orexigenic effects

    High

    Human studies show increased food intake, roughly 36% in healthy men.

    PMID 15699539 (Laferrere 2005, healthy men); PMC2824649 (Laferrere 2006, obese subjects)

  • GH axis reactivation in critical illness

    Medium

    Small human trials normalized IGF-I and related growth markers in critically ill patients.

    PMID 9024260 (Van den Berghe 1997 GHRH+GHRP-2 infusion RCT); PMID 10037246 (synchronized GH/TSH/PRL); PMID 10199772; PMID 12030918

  • Enhanced body composition

    Speculative

    No human body-composition trials located. One mouse study showed added fat, not lean mass.

    PMID 11796511 (Tschop 2002, GHRP-2 increases fat not lean mass in mice); no human body-composition RCT located

  • Improved sleep quality

    Speculative

    The main cited study found no role for GHRP in human slow-wave sleep.

    PMID 9612233 (Moreno-Reyes 1998, 'Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation')

  • Synergistic effects with GHRH

    High

    Human trials show combined GHRH and GHRP-2 give a larger GH response than either alone.

    PMID 9024260 (Van den Berghe 1997 GHRH+GHRP-2); PMID 9285939 (Arvat 1997)

Benefits(7)

  • Potent growth hormone release

  • Diagnostic tool for GH deficiency

  • Appetite stimulation and orexigenic effects

  • GH axis reactivation in critical illness

  • Enhanced body composition

  • Improved sleep quality

  • Synergistic effects with GHRH

Key studies(6)

  1. Laferrère B, Abraham C, Russell CD, Bowers CY

    J Clin Endocrinol Metab

    2005

    GHRP-2 infusion (1 mcg/kg/h SC) increased food intake by 35.9% (p=0.004) and GH AUC 13.5-fold (p=0.003) vs placebo in healthy men

  2. Suzuki S, Ruike Y, Ishiwata K, Naito K, Igarashi K, Ishida A, Fujimoto M, Koide H, Horiguchi K, Tatsuno I, Yokote K

    J Endocr Soc

    2022

    GHRP-2 test combined with ACTH measurement detects secondary adrenal insufficiency with 83% sensitivity and 88% specificity; 94% of secondary AI cases occurred with severe GHD

  3. Pihoker C, Kearns GL, French D, Bowers CY

    J Clin Endocrinol Metab

    1998

    GHRP-2 (1 mcg/kg IV) produced biexponential PK with t½=33 min, Cmax=7.4 ng/mL, EC50=1.09 ng/mL, and maximum GH effect of 67.5 ng/mL in prepubertal children

  4. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R

    Clin Endocrinol (Oxf)

    2002

    GHRP-2 alone (1 mcg/kg/h) reactivated GH secretion and normalized IGF-I, IGFBP-3, and ALS in critically ill men; triple therapy (GHRP-2+TRH+GnRH) showed superior metabolic effects

  5. Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man

    Comparative controlled study12Single-dose IV administration

    Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E

    Peptides

    1997

    GHRP-2 and hexarelin show similar GH-releasing potency exceeding GHRH (p<0.05); both elevate prolactin, ACTH, and cortisol comparably to CRH stimulation in young and elderly subjects

  6. Diagnostic studies with intravenous and intranasal GHRP-2 in children of short stature

    Diagnostic clinical trial24Single-dose IV and intranasal administration

    Pihoker C, Middleton R, Reynolds GA, Bowers CY, Badger TM

    J Clin Endocrinol Metab

    1995

    GHRP-2 equally reliable as GHRH for predicting pituitary GH reserve; intranasal GHRP-2 (15 mcg/kg) produced peak GH of 31.3 mcg/L; GHRH+GHRP-2 combination produced synergistic responses

What research suggests over time

  • Hours-Days

    Phase I/II

    Acute GH pulse on injection (Cmax ~7.4 ng/mL, t½ ~33 min); appetite increase of ~36% reported in healthy volunteers vs placebo.

  • Weeks 2-4

    Diagnostic clinical use

    Sustained GH release with chronic dosing; some clinical use as a diagnostic GH-stimulation test for adrenal insufficiency.

  • Long-term

    Phase I/II

    Used as a diagnostic stimulation test in Japan; not FDA-approved. US compounding status is 503A Category 3 and 503B Category 2 for injectable/nasal routes, with other 503B routes in Category 1 under conditional enforcement discretion.

Regulation & availability

Why researchers look at it

One of the most potent GH secretagogues ever tested in humans, driving up to 13-fold GH increases over placebo and reaching Phase II trials — it's the only peptide in its class clinically approved anywhere (as a diagnostic in Japan). However, it also raises cortisol, prolactin, and appetite by ~36%, side effects that cleaner alternatives like ipamorelin avoid. For US bulk compounding, it is in 503A Category 3; under 503B, injectable/nasal routes are Category 2 and other routes are Category 1 under conditional enforcement discretion.

Estimated cost
No approved product and no verified reference price
FDA status
Not FDA-approved for any indication. GHRP-2 is in 503A Category 3. Under 503B, injectable and nasal routes are Category 2; other routes are Category 1 under the interim policy's conditions. FDA cites immunogenicity, peptide impurities and characterization concerns, plus serious adverse-event reports with causality unestablished. Japan approves it for diagnosing GH deficiency.
WADA status
Prohibited at all times (in and out of competition) — classified under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics on the WADA Prohibited List. Specifically listed as a growth hormone secretagogue / GHS-R agonist. This classification continued unchanged in the 2026 WADA Prohibited List, effective January 1, 2026. Detection methods include urine and blood testing for the parent compound and metabolites.
Prescribability
Not FDA-approved. For bulk compounding, GHRP-2 is in 503A Category 3; under 503B, injectable and nasal routes are Category 2 and other routes are Category 1 under conditional enforcement discretion. Japan approves GHRP KAKEN100 Injection for diagnosing GH deficiency.
Availability
Very limited legitimate availability. Japan authorizes GHRP KAKEN100 Injection (Kaken Pharmaceutical) for diagnosing GH deficiency. GHRP-2 is not FDA-approved. US bulk compounding is not covered by Category 1 discretion under 503A or for injectable/nasal use under 503B. Other 503B routes are Category 1, subject to the interim policy's conditions.

International status

  • EU

    Not approved

  • US

    Not FDA-approved. 503A Category 3; under 503B, injectable and nasal routes are Category 2 and other routes are Category 1 under conditional enforcement discretion.

  • Australia

    Banned substance (WADA/Sports)

Regulatory timeline(11)

  1. 1995
    First clinical diagnostic studies of GHRP-2 in children with short stature published (Pihoker et al., JCEM)
  2. 1997
    Comparative endocrine study vs hexarelin published showing similar GH-releasing potency (Arvat et al., Peptides)
  3. 1998
    Phase I pharmacokinetic/pharmacodynamic study completed in prepubertal children (Pihoker et al., JCEM)
  4. Early 2000s
    Phase II clinical trials for GH deficiency treatment conducted but ultimately discontinued — efficacy significantly reduced in GHD patients vs healthy subjects
  5. 2002
    Randomized controlled trial in critically ill men published (Van den Berghe et al., Clin Endocrinol)
  6. ~2004
    Approved in Japan as diagnostic agent for GH deficiency — marketed as GHRP Kaken 100 by Kaken Pharmaceutical
  7. 2005
    Key food intake study confirming ghrelin-like orexigenic effects published (Laferrère et al., JCEM)
  8. 2008-present
    WADA prohibits GH secretagogues including GHRP-2 under S2 category — prohibition maintained through 2026 list
  9. 2022
    Novel diagnostic utility demonstrated: GHRP-2 test detects secondary adrenal insufficiency alongside GHD (Suzuki et al., J Endocr Soc)
  10. 2023-09-29
    FDA places injectable and nasal GHRP-2 in 503B Category 2. Its 503A placement is Category 3.
  11. 2026
    Current FDA lists place GHRP-2 in 503A Category 3; under 503B, injectable/nasal routes are Category 2 and other routes are Category 1.

Sources & FAQs

Research sources(10)

Frequently asked questions(5)

How does GHRP-2 differ from GHRP-6?

GHRP-2 is considered the more potent GH secretagogue with somewhat less appetite stimulation than GHRP-6, though both significantly increase hunger. GHRP-2 also has a slightly different amino acid sequence (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂ vs GHRP-6's His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) and was the first GHS-R agonist introduced clinically.

How does GHRP-2 compare to ipamorelin?

GHRP-2 produces stronger GH release but also significantly elevates cortisol, prolactin, and ACTH — effects largely absent with ipamorelin.

Is GHRP-2 approved for medical use anywhere?

Yes, but only in Japan and only as a diagnostic agent. Kaken Pharmaceutical markets it as GHRP Kaken 100 for single-dose assessment of growth hormone deficiency. It is not approved for therapeutic (treatment) use in any country.

Can athletes use GHRP-2?

No. GHRP-2 is prohibited at all times (in and out of competition) by WADA under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. This applies to all competitive and Olympic-level sport. It has been on the prohibited list since the GHS-R agonist class was added.

Does GHRP-2 work for treating GH deficiency?

GHRP-2 reached Phase II trials for GHD treatment but was never approved because its ability to increase GH levels is significantly lower in people with actual GH deficiency compared to healthy individuals. This limits its therapeutic utility for the condition it diagnoses.